Low‐dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter

BACKGROUND: The first‐line therapy is effective for the treatment of primary immune thrombocytopenia (ITP); however, maintaining the long‐term responses remains challenging. Low‐dose decitabine (DAC) has been adopted to treat refractory ITP, while its role in macrophage polarization has not been ful...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Xia, Xu, Pengcheng, Ji, Lili, Wu, Boting, Zhan, Yanxia, Zhuang, Xibing, Ou, Yang, Hua, Fanli, Sun, Lihua, Li, Feng, Wang, Xiangdong, Chen, Hao, Cheng, Yunfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366349/
https://www.ncbi.nlm.nih.gov/pubmed/37488670
http://dx.doi.org/10.1002/ctm2.1344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366349/
https://www.ncbi.nlm.nih.gov/pubmed/37488670
http://dx.doi.org/10.1002/ctm2.1344

Ejemplares similares